Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients

被引:9
|
作者
Macedo, Luciana Conci [1 ]
Quintero, Fernanda de Cesare [2 ]
Pagliari-E-Silva, Sara [3 ]
Barbosa Pagnano, Katia Borgia [4 ]
Rodrigues, Camila [1 ]
de Alencar, Josiane Bazzo [1 ]
Sell, Ana Maria [2 ]
Laguila Visentainer, Jeane Eliete [2 ]
机构
[1] Univ Estadual Maringa, Biomed & Clin Anal Dept, Post Grad Program Biosci & Physiopathol, BR-87020900 Maringa, Parana, Brazil
[2] Univ Estadual Maringa, Basic Hlth Sci Dept, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
[3] Hosp Canc Maringa, Maringa, Parana, Brazil
[4] Univ Estadual Campinas, Ctr Hematol & Hemoterapia Campinas, Sao Paulo, Brazil
关键词
Myeloproliferative disorders; NECROSIS-FACTOR-ALPHA; PROMOTER POLYMORPHISM; GENETIC POLYMORPHISMS; POLYCYTHEMIA-VERA; SUSCEPTIBILITY; LUNG; REGION;
D O I
10.1016/j.bcmd.2015.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classical chromosome Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of disorders that share clinical, hematological, and histological features. Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) are elevated in patients with MPN. The aim of this study was to verify the association between the polymorphisms of TNF gene (-308G/A and-238 G/A) in BCR-ABL-negative MPN in our population. Blood samples obtained from MPN patients were genotyped for the JAK2V617F mutation and both TNF polymorphisms using PCR-RFLP. Thirty three (26.8%) patients with polycythemia vera (PV), 35 (28.7%) essential thrombocythemia (ET), 22 (17.7%) primary myelofibrosis (PMF), and 33 (26.8%) with unclassifiable MPN (MPNu) were included in the study. The JAK2 V617F mutation was detected in 94 (76.42%) patients. Were observed a significant increase on the frequency of the TNF-238 GA genotype in MPN patients compared to controls (OR = 221, 95% Cl = 1.02-4.80, P < 0.04). The distribution of the genotypes and allelic frequencies of TNF-308 was significantly different among the MPNs, JAK2V617F positive, PV and PMF, and controls. Our data has demonstrated that the polymorphisms on TNF-238 GA, TNF-308 GA were associated to MPN development in this population, triggered by JAK2 V617F mutation. (C) 2015 Published by Elsevier Inc.
引用
收藏
页码:54 / 57
页数:4
相关论文
共 50 条
  • [41] SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F
    Koren-Michowitz, Maya
    Gery, Sigal
    Tabayashi, Takayuki
    Lin, Dechen
    Alvarez, Rocio
    Nagler, Arnon
    Koeffler, H. Phillip
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (06) : 811 - 820
  • [42] JAK2 V617F down-modulates MPL
    Fleischman, Angela G.
    Tyner, Jeffrey W.
    BLOOD, 2012, 119 (20) : 4579 - 4580
  • [43] The prevalence of the JAK2 V617F Exon 14 mutation in Sudanese patients with Myelo Proliferative Neoplasms (MPNs)
    Yasin, Elrashed B.
    Kordofani, Anwaar A. Y.
    Elamin, Bahaeldin K.
    Dallol, A.
    BIOSCIENCE RESEARCH, 2019, 16 (03): : 2423 - 2429
  • [44] Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia
    Kearney, Laura
    Lee Tokar, Lisa
    Flynn, Catherine
    Mykytiv, Vitaliy
    Murphy, Karen
    Langabeer, Stephen E.
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (11) : 772 - 772
  • [45] A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
    Kilpivaara, Outi
    Mukherjee, Semanti
    Schram, Alison M.
    Wadleigh, Martha
    Mullally, Ann
    Ebert, Benjamin L.
    Bass, Adam
    Marubayashi, Sachie
    Heguy, Adriana
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Offit, Kenneth
    Stone, Richard M.
    Gilliland, D. Gary
    Klein, Robert J.
    Levine, Ross L.
    NATURE GENETICS, 2009, 41 (04) : 455 - 459
  • [46] Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes, Raoul
    Mesa, Ruben A.
    LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1178 - 1187
  • [47] Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms
    Bourrienne, Marie-Charlotte
    Loyau, Stephane
    Faille, Dorothee
    Gay, Juliette
    Akhenak, Selena
    Farkh, Carine
    Ollivier, Vronique
    Solonomenjanahary, Mialitiana
    Dupont, Sbastien
    Choqueux, Christine
    Villeval, Jean-Luc
    Plo, Isabelle
    Edmond, Valerie
    Ho-Tin-Noe, Benoit
    Ajzenberg, Nadine
    Mazighi, Mikael
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (11) : 3199 - 3208
  • [48] Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases
    Inmaculada Rapado
    Enriqueta Albizua
    Rosa Ayala
    Jose Angel Hernández
    Luis Garcia-Alonso
    Silvia Grande
    Miguel Gallardo
    Florinda Gilsanz
    Joaquin Martinez-Lopez
    Annals of Hematology, 2008, 87 : 741 - 749
  • [49] The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective
    Wadleigh M.
    Gilliland D.G.
    Current Hematologic Malignancy Reports, 2006, 1 (2) : 75 - 80
  • [50] Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib
    Damien Luque Paz
    Jean-Christophe Ianotto
    Aurélie Chauveau
    Briac Guibourg
    Lydie Lecucq
    Eric Lippert
    Valérie Ugo
    Annals of Hematology, 2016, 95 : 349 - 350